Articles On Suda Pharmaceuticals (ASX:SUD)

Summary SUDA Pharmaceuticals (ASX:SUD) is a leading oro-mucosal drug delivery leader based in Australia. The Company’s management is presently working with the technical team to further bolster the intellectual property portfolio as it...

The receipt of $662,000 in additional funding will further support SUDA’s development work for the current year.

Summary SUDA Pharmaceuticals Ltd (ASX:SUD) recently released its quarterly activities report for the first-quarter FY 2021. The quarter marked the attainment of two important milestones for the anagrelide program and receipt of TGA appr...

Summary SUDA Pharmaceuticals (ASX:SUD) has recently published its October 2020 newsletter for shareholders, outlining developments around its key projects – ZolpiMist® and anagrelide. Lately, SUDA has made significant progress with re.....

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The capital raising wave shows no sign of crashing with August’s total coming in at $4.7bn. Once again resources companies raised more than any other sector — $163m of the $296m raised by companies with market capitalisations below $100m. F...

A quick wrap of the ASX’s key winners and losers on Monday, August 31. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 838 stocks rose, 662 declined and 5...

As pot-stock aficionados know, investing in cannabis means navigating a labyrinth of regulatory developments which differ by jurisdiction. The latest big name in healthcare to weigh in is the American Heart Association, which this week rele...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

A quick wrap of the ASX’s key winners and losers on Thursday, July 30. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 783 stocks rose, 532 declined and 7...

Perth-based SUDA Pharmaceuticals (ASX:SUD) has announced the TGA has approved its lead product ZolpiMist (zolpidem tartrate) for the treatment of short-term insomnia in adults.

SUDA Pharmaceuticals Limited (ASX:SUD) soared above 150 per cent to $0.068 on ASX on 29 July 2020, following the announcement regarding grant of Therapeutics Goods Administration’s (TGA) approval for ZolpiMistTM (zolpidem tartrate). Notably...

A quick wrap of the ASX’s key winners and losers on Wednesday, July 29. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 529 stocks rose, 801 declined and...

The Suda Pharmaceuticals Ltd (ASX: SUD) share price has soared 207.4% today, at the time of writing. The surge came following the company’s announcement that its Zolpimist product has been approved by the TGA (Therapeutic Goods Administrat...

Perth-based SUDA Pharmaceuticals (ASX: SUD) has received approval from the Therapeutics Goods Administration for its ZolpiMist oral spray to be used in the treatment of short-term adult insomnia. The company has also been approved as a supp...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

SUDA Pharmaceuticals Limited (ASX:SUD), the global leader in reformulating and delivering medication via the oral mucosa is seeking shareholders’ support to participate in the capital raising activity announced in early July 2020. On 3rd J...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Suda’s lead product ZolpiMist is the oro-mucosal spray version of the blockbuster insomnia drug Ambien, which has 30 million prescriptions written for it in the US annually.

Australia’s oro-mucosal drug delivery leader, SUDA Pharmaceuticals Limited (ASX:SUD) has recently announced a non-renounceable entitlement offer to raise about $3.56 million via issue of ~142 million new ordinary shares in SUDA, at an attra...

The Japanese Patent Office has accepted Anagrelide cancer patent application, and the patent would now proceed to grant, notified SUDA Pharmaceuticals Ltd (ASX:SUD) in its latest update. The patent “Use of Anagrelide for Treating Cancer” .....

SUDA Pharmaceuticals Limited (ASX:SUD), an Australia-based oro-mucosal drug delivery player, notified in its latest update that the Therapeutic Goods Administration (TGA) review for its insomnia drug ZolpiMistTM is expected to be completed...

ASX shares can help you build a diversified dividend portfolio. In this coronavirus era, finding those shares that can grow or even just maintain their dividend is very valuable. Just look at shares like National Australia Bank Ltd (ASX: N...

Oro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) has announced another set of robust quarterly results for the third quarter of FY2020. During the period, the Company made considerable progress in line with the 2020...

The company develops oral sprays using its OroMist® technology to reformulate existing pharmaceuticals

In a recent letter to its top shareholders, Perth-based oro-mucosal drug delivery company SUDA Pharmaceuticals Ltd (ASX:SUD) has outlined the steps it is taking amidst COVID-19 pandemic, that has so far infected more than 780,000 people and...

The company recently entered into an exclusive licence agreement with South Korean subsidiary of Mitsubishi Tanabe Pharma Corporation.

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Progressing remarkably with the commercialisation of its insomnia drug ZolpiMistTM, the oro-mucosal drug delivery leader SUDA Pharmaceuticals Limited (ASX:SUD) has signed an additional licence agreement with one of the top Japanese pharmace...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr Michael Baker, CEO of Suda Pharmace...

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to foc...

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to foc...

Continuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to foc...

Few people are at their desks in the week between Christmas and new year, which means it’s a prime dumping period for companies wanting to hide bad news. But there’s always someone who draws the short straw in a newsroom and this year it wa...

Viagra mouth spray maker SUDA Pharmaceuticals (ASX:SUD) has talked a multi-billion dollar pharmaceutical company into backing its tech. Sanofi-Aventis has signed a feasibility agreement to test the mouth spray technology with one of its own...

SUDA Pharmaceuticals (ASX:SUD) has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, a Spanish pharmaceutical company that focuses on nutrition, health and well-being.

A novel product for the consumer paediatric market could soon be developed after drug delivery specialist Suda Pharmaceuticals (ASX: SUD) announced a fully-funded feasibility study and option agreement with Spanish pharmaceutical company La...

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

SUDA Pharmaceuticals (ASX:SUD), a company focused on oro-mucosal drug delivery, has announced the appointment of Dr Michael Baker as its CEO, commencing 2 January 2020.

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

Thailand has not yet legalised marijuana but pretty soon Thais will not only be able to grow their own plants but they will be allowed to sell them to the government. “In the near future, families will be able to plant cannabis trees in the...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

James Dean is returning to the silver screens after a six and a half decade absence. The Rebel Without A Cause star passed away in a car crash in 1955 but he will be starring in the Vietnam War era drama Finding Jack. Of course filmmakers a...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...